Determining Regulators Of ILC3 In Mucosal Barrier Function And Immune Homeostasis
Funder
National Health and Medical Research Council
Funding Amount
$705,209.00
Summary
Innate lymphoid cells (ILCs) are specialized cells that defend the body against invading microorganisms at the body’s surfaces, mediate pathogen clearance and tissue repair but may also drive inflammatory conditions such as allergic asthma and inflammatory bowel disease. We will investigate the molecular switches that regulate this novel cell type and potentially uncover novel molecules or pathways for therapeutic targets.
Professor Godfrey is an immunologist with a long standing history as a pioneer in the study of a specialised type of white blood cell, known as NKT cells. NKT cells are activated in response to lipid-based molecules that are thought to alert the immune system, via NKT cell activation, to the presence of infectious agents or other abnormalities. A better understanding of how NKT cells function will provide new approaches to battling a broad range of diseases where these cells are implicated, incl ....Professor Godfrey is an immunologist with a long standing history as a pioneer in the study of a specialised type of white blood cell, known as NKT cells. NKT cells are activated in response to lipid-based molecules that are thought to alert the immune system, via NKT cell activation, to the presence of infectious agents or other abnormalities. A better understanding of how NKT cells function will provide new approaches to battling a broad range of diseases where these cells are implicated, including cancer, autoimmunity, allergy and infection.Read moreRead less
Deciphering The Role Of Intron Retention In Monocyte Differentiation And Function
Funder
National Health and Medical Research Council
Funding Amount
$511,114.00
Summary
In 2013, we made a breakthrough discovery that certain parts of genes, previously considered “Junk DNA”, are actually carrying signals to control the amount of proteins produced in cells. We now wish to understand the roles of these signals in the development of a key immune cell called monocyte. Monocytes are important to fight infection and inflammation in diseases such as diabetes and cancer. We hope to advance our knowledge on how we can manipulate these cells for therapeutic gain.
Organisation Of The Genome During The Development Of Antibody-secreting Cells
Funder
National Health and Medical Research Council
Funding Amount
$886,155.00
Summary
Each cell of our body contains over two metres of DNA that must be correctly packaged in order for our cells to function. We are using cutting-edge molecular biology techniques to study how this DNA circuitry is established in the white blood cells of our immune system that produce antibodies. Our novel approaches will reveal unique strategies to modulate immune responses to our benefit.
Induction Of Natural T-Regulatory Cells By Thymic Dendritic Cell Populations
Funder
National Health and Medical Research Council
Funding Amount
$413,775.00
Summary
In this study, we will determine the roles of the antigen presenting cells, namely denderitic cells, in the induction of T-regulatory cell (T-reg) developemnt in the thymus. T-reg cells play important roles in controlling the development of autoimmunity. This study will help to understand the possible causes of autoimmune diseases and to develop new treatments for these diseases.
Maternal Gut Microbiome During Pregnancy Influences Offspring Atopy And Asthma.
Funder
National Health and Medical Research Council
Funding Amount
$46,622.00
Summary
Allergic diseases such as food allergy and asthma have increased significantly as our exposure to bacteria has reduced. Many studies have explored exposure to bacteria in early life but few have examined the maternal bacteria we are exposed to while we develop in the womb. New studies indicate that we are exposed to many different components of our mothers gut bacteria and this might change our developing immune system and determine whether or not we get diseases like food allergy and asthma.
This application will increase the impact of cancer immunotherapy on disease prevention and treatment, by developing new targets and novel combination immunotherapies. Outcomes will include an improved understanding of the immune reaction with cancer and more effective strategies to prevent cancer spread and safely target and eradicate a larger proportion of established and advanced malignant disease.
Understanding And Modulating The Human Immune System
Funder
National Health and Medical Research Council
Funding Amount
$470,144.00
Summary
T cells are the sentinels of our immune system continually scanning our tissue for abnormalities and eliminating threats in many forms. They are our second and last line of defence against microorganisms and cancer. Unfortunately, T cells can also cause harm through accidental crossreactvity or overzealous function. My work is directed at understanding how T cells work and how they can be controlled using drugs and gene therapy. If we can ‘tune’ the power of this master immune lineage we can unl
Advancement Of A Personalised Approach To Minimising Infective Complications In Cancer Care
Funder
National Health and Medical Research Council
Funding Amount
$265,138.00
Summary
Managing infections in patients with cancer have become more difficult and unpredictable because of new generation cancer therapies. Measuring the response of the immune system (immune profiling) will allow us to predict which patients will develop infection so that action such as vaccination can be taken to reduce their risk. This program will refine immune profiling to personalise infection care for cancer patients and to introduce it into hospital practice.
Functional Assessment Of CD40 In The Development Of Multiple Sclerosis
Funder
National Health and Medical Research Council
Funding Amount
$521,910.00
Summary
Many of the genes which affect susceptibility to Multiple Sclerosis (MS) have recently been identified. Two of these genes were first discovered in an Australian study published in Nature Genetics in 2009. One of these is CD40, which controls immune cell activation. In this project we aim to establish how the genetic variant identified affects the function of the CD40 gene in MS. CD40 may prove to be a good therapeutic target, with agents available to modulate CD40 available already.